IBM, Illumina, Munich Leukemia Laboratory to Develop Genomic Analysis Tech for Leukemia, Lymphoma

NEW YORK (GenomeWeb) – Munich Leukemia Laboratory (MLL) has begun a collaboration with IBM and Illumina to develop a new cognitive technology prototype for providing personalized leukemia and lymphoma treatments.

The project will use IBM’s Watson and MLL will be the first European adopter of the Illumina high-throughput sequencing NovaSeq platform.

Get the full story This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?

Be the first to comment

Leave a Reply

Your email address will not be published.